IDS has announced that one of its partners - Technogenetics - has signed a contract with A Menarini Designs which will see it supply the firm with tests for the diagnosis of autoimmune diseases.
Through its collaboration with Technogenetics, IDS will work to produce a new automated test system entitled the Zenit RA, as well as a collection of 21 tests for the diagnosis of autoimmune diseases.
The five-year distribution agreement covers the whole of Europe and countries of the former Soviet Union, such as Russia and Ukraine.
Chief executive officer of IDS Roger Duggan commented: "The deal signed between Technogenetics and Menarini significantly expands the route to market for Technogenetics' autoimmune products. This can only enhance future sales of IDS-manufactured instruments and ancillary reagents across Europe."
This news follows the announcement last month that IDS has appointed a new non-executive director - Dr Patrik Olof Dahlen - the current chief executive officer of the point-of-care diagnostics firm Chempaq A/S.
